PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Certificate of Amendment to Articles of Incorporation

On September 20, 2019, the Company filed with the Secretary of the State of the State of Nevada a Certificate of Amendment to Articles of Incorporation (“Amendment”). The Amendment amended Article IV of the Company’s Articles of Incorporation to provide that the Board of Directors has the power to designate the powers, preferences, rights, qualifications, limitations and restrictions pertaining to the preferred stock of the Company. The Amendment did not adjust the number of authorized shares of the common stock or preferred stock of the Company, or the par value thereof, or any other rights or preferences of the common stock or preferred stock of the Company.

The foregoing description of the Amendment is qualified in its entirety by reference to the complete terms and conditions of the Certificate of Amendment to Articles of Incorporation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated by reference into this Item 5.03.

 

Certificate of Designations of Preferences and Rights of Series A Preferred Stock

On September 27, 2019, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designations of Preferences and Rights of Series A Preferred Stock (“Designation”). The Designation authorized one (1) share of Series A Preferred Stock, par value $0.0001 per share. The Series A Preferred Stock does not have specific liquidation, transfer, conversion or dividend rights, and may be redeemed at any time by the Company for a redemption price of $1.00 paid to the holder of the Series A Preferred Stock. The Certificate of Designations does grant the holder of the Series A Preferred Stock certain voting rights, with the share of Series A Preferred Stock having a number of votes at any time equal to the number of votes then held or entitled to be made by all other equity securities of the Company, including, without limitation, the Common Stock, debt securities of the Company or to any other agreement, contract or understanding of the Company, thus granting the Series A Preferred Stock holder, if and when the Series A Preferred Stock is issued, voting control of the Company. The Series A Preferred Stock has not been issued at this time. In addition, the Series A Preferred Stock contains protective provisions that require the affirmative vote or written consent of the Series A Holder, with the share of the Series A Preferred Stock have one (1) vote on such matter, to: (i) amend or repeal any provision of the Certificate of Designation, including by merger, consolidation or otherwise; (ii) amend or repeal any provision of, or add any provision to, the Articles or bylaws of the Company is such action would adversely alter or change the preferences, rights, privileges, or powers of, or restrictions provided for the benefit of, the Series A Preferred Stock.

The foregoing description of the Designation is qualified in its entirety by reference to the complete terms and conditions of the Designation of Series A Preferred Stock, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.2 and is incorporated by reference into this Item 5.03.

Item 9.01 Financial Statements and Exhibits.

(d)  Exhibits.

 


PharmaCyte Biotech, Inc. Exhibit
EX-3.1 2 pharm_ex0301.htm CERTIFICATE OF AMENDMENT Exhibit 3.1   CERTIFICATE OF AMENDMENT   (pursuant to NRS 78.385 and 78.390)   Certificate of Amendment to Articles of Incorporation   of   PharmaCyte Biotech,…
To view the full exhibit click here

Story continues below

About PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB)

PharmaCyte Biotech, Inc., formerly Nuvilex, Inc., is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Company’s Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. The Company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type I diabetes and insulin-dependent Type II diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using its Cell-in-a-Box technology.

An ad to help with our costs